10 months ago
Bharat Biotech Establishes Nucelion Therapeutics for Cell & Gene Therapies
Imagine a special kind of medicine that can fix diseases by changing a person's own cells or genes.
Bharat Biotech, a company that makes vaccines, has started a new company called Nucelion Therapeutics.
This new company will help other scientists and doctors create these special cell and gene medicines.
Nucelion will build these medicines, from making the very first steps in the lab to producing a lot of them for people to use.
They will make sure these medicines are safe and meet the rules of countries like the United States and Europe.
Nucelion's goal is to help create cures for serious illnesses like cancer and rare genetic problems, making these advanced treatments available to more people.
Bharat Biotech International has launched Nucelion Therapeutics as a wholly-owned subsidiary.
Nucelion Therapeutics is a Contract Research Development and Manufacturing Organisation (CRDMO) specializing in cell and gene therapies.
The CRDMO is located in Genome Valley and will offer process development and manufacturing for advanced therapies.
Services include the development and manufacturing of plasmid DNA, viral vectors, and cell therapies, aiming for clinical to commercial scale.
Nucelion has commissioned a GMP facility and will adhere to global regulatory standards like FDA and EMA.
- Who
- Bharat Biotech International
- What
- Established Nucelion Therapeutics, a wholly-owned subsidiary and Contract Research Development and Manufacturing Organisation (CRDMO) focused on cell and gene therapies.
- Where
- Genome Valley, Hyderabad
- When
- Published on November 3, 2025
- Why
- To support global life science innovators with scalable process development and manufacturing solutions for advanced therapies targeting cancers, autoimmune disorders, and rare genetic disorders, and to integrate advanced therapy platforms into India's healthcare ecosystem.
Key facts
- Company Name
- Nucelion Therapeutics
- Parent Company
- Bharat Biotech International
- Focus Area
- Cell and Gene Therapies (CGTs)
- Services Offered
- Process development, manufacturing of plasmid DNA, viral vectors, autologous and allogeneic cell therapies
- Location
- Genome Valley, Hyderabad
- Regulatory Compliance
- FDA, EMA standards
Quotes
Krishna Ella
Non-Executive Director, Nucelion Therapeutics
“The future of pharmaceutical innovation will be biological; CGTs are a key vector. Our vision is to integrate advanced therapy platforms into India’s healthcare ecosystem, enabling equitable solutions for complex and rare diseases.”
thehindubusinessline.com
